In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Indaptus Therapeutics (INDP – Research Report). The company’s shares closed yesterday at $1.62.
According to TipRanks, McCarthy is an analyst with an average return of -33.9% and a 15.65% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Achieve Life Sciences, BioNano Genomics, and Lineage Therap.
Indaptus Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00, representing an 825.93% upside. In a report released on March 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $4.25 and a one-year low of $1.25. Currently, Indaptus Therapeutics has an average volume of 9,598.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
Read More on INDP:
- Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
- Indaptus Therapeutics reports 2022 EPS ($1.73) vs ($1.89) last year
- Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023
- Indaptus Therapeutics activates Emory Winship Cancer Institute as trial site
- Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
